Business Context and Reporting Period
This Form 8-K Current Report was filed by GRI Bio, Inc. on May 23, 2025. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "GRI". The report addresses a specific corporate action regarding its equity financing program.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The only financial figures disclosed relate to the Company's At The Market (ATM) Offering Agreement:
- Additional Shares Authorized: Up to an aggregate gross sales price of $1,758,934.
- Shares Previously Sold: Approximately $4,546,137 in aggregate gross sales price sold to date under the Sales Agreement dated May 20, 2024.
- Total ATM Capacity: Approximately $6,305,071 (sum of previously sold and newly authorized amounts).
Material Changes
The material change reported is the amendment of the Sales Agreement with H.C. Wainwright & Co., LLC. The Company filed a prospectus supplement to increase the maximum number of shares issuable under the agreement by $1,758,934. This action expands the Company's ability to raise capital through the existing ATM facility.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or a discussion of specific risks and contingencies beyond the standard legal opinion regarding the share issuance. The primary focus is the administrative update to the equity offering program.
Investor Verification Checklist
- Verify the total number of shares authorized for issuance under the amended Sales Agreement.
- Confirm the current market price of GRI Bio common stock to estimate the share count associated with the $1,758,934 increase.
- Review the full text of the prospectus supplement (Exhibit 5.1) for any new terms or conditions attached to the additional shares.
- Check subsequent filings for actual sales activity under the expanded ATM facility.